Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial

By sjmartinez • January 21, 2025

Goldman JW, Bueno AM, Dooms C, Jhaveri K, de Miguel M, Piha-Paul SA, Unni N, Zick A, Mahipal A, Suga JM, Naltet C, Antoñanzas M, Crown J, Bebchuk J, Eli LD, Lowenthal BH, Mahalingam D. Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial. Clin Lung Cancer. 2024 Dec 11:S1525-7304(24)00266-3. doi: 10.1016/j.cllc.2024.12.003. Epub ahead of print. PMID: 39828466.

Tags: Basket study, Hematology/Oncology, NSCLC, Objective response rate, Publications, Rare mutations, Tyrosine kinase inhibitor

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis[...]

Pregnancy and breast cancer in young women: current updates and future directions

Zhang S, Guclu SB, Lipsyc-Sharf M, Kapoor NS. Pregnancy and breast cancer in young women: current updates and future directions. Ther Adv Med Oncol. 2025[...]

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

Falchi L, Sureda A, Leppä S, Vermaat JS, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton K,[...]